Emerging problem pathogens: A review of resistance patterns over time

被引:14
作者
Akova, Murat [1 ]
机构
[1] Hacettepe Univ, Sch Med, Dept Med, Infect Dis Sect, TR-06100 Ankara, Turkey
关键词
antibiotic resistance;
D O I
10.1016/S1201-9712(06)60002-7
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Despite the advances in chemotherapy for cancer patients, infectious complications remain an important cause of mortality and morbidity. Surveillance data report not only a shift in the aetiology of infections and resistance patterns in this patient population, but also important differences between regions and countries. Viridans streptococcal bacteraemias are common among cancer patients being second only to the coagulase-negative staphytococci. However, in certain centres in Europe Gram-negative bacilli have once again become the predominant infecting pathogens. The problems associated with emerging resistance have been widely documented in the literature. In some institutions methicillin-resistance among coagulase-negative staphytococci has reached 75%, and in others the incidence of extended-spectrum beta-lactamase producing Gram-negative bacilli has risen markedly. These shifts in antimicrobial susceptibility are important in guiding the choice of agents for febrile neutropenia. Antibiotic use and prophylaxis have both been associated with changes in susceptibility, and prescribing habits may influence emerging resistance. In this context, the choice of empirical antibiotic therapy and the use of prophylaxis should be driven by a sound understanding of local circumstances. (c) 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:S3 / S8
页数:6
相关论文
共 29 条
[11]  
DEBOCK R, 2001, 41 INT C ANT AG CHEM, P455
[12]   Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States [J].
Doern, GV ;
Ferraro, MJ ;
Brueggemann, AB ;
Ruoff, KL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (04) :891-894
[13]  
GAFTERGVILI A, 2006, EUR C CLIN MICR INF, pP685
[14]   Viridans streptococci isolated by culture from blood of cancer patients: Clinical and microbiologic analysis of 50 cases [J].
Han, XY ;
Kamana, M ;
Rolston, KVI .
JOURNAL OF CLINICAL MICROBIOLOGY, 2006, 44 (01) :160-165
[15]   Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004) [J].
Jones, RN ;
Stilwell, MG ;
Sader, HS ;
Fritsche, TR ;
Goldstein, BP .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2006, 54 (02) :149-153
[16]   Fluoroquinolone resistance of Escherichia coli at a cancer center:: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia [J].
Kern, WV ;
Klose, K ;
Jellen-Ritter, AS ;
Oethinger, M ;
Bohnert, J ;
Kern, P ;
Reuter, S ;
von Baum, H ;
Marre, R .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2005, 24 (02) :111-118
[17]   Serious complications of bacteremia caused by Viridans streptococci in neutropenic patients with cancer [J].
Marron, A ;
Carratalà, J ;
González-Barca, E ;
Fernández-Sevilla, A ;
Alcaide, F ;
Gudiol, F .
CLINICAL INFECTIOUS DISEASES, 2000, 31 (05) :1126-1130
[18]   Unit differences in pathogen occurrence arising from the MYSTIC Program European database (1997-2000) [J].
Mendes, C ;
Turner, PJ .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2001, 41 (04) :191-196
[19]   Extended-spectrum β-lactamases and clinical outcomes:: Current data [J].
Ramphal, R ;
Ambrose, PG .
CLINICAL INFECTIOUS DISEASES, 2006, 42 :S164-S172
[20]  
SAFDAR P, 2006, EUR C CLIN MICR INF, P681